UDENYCA
Peakpegfilgrastim-cbqv
BLAINJECTIONINJECTABLE
Approved
Nov 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
3/8 — Basic
Drug data last refreshed 2h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
UDENYCA is a biosimilar pegfilgrastim (pegfilgrastim-cbqv) approved in 2018 as a granulocyte colony-stimulating factor (G-CSF) analog. It is indicated to reduce the incidence of fever and infection in cancer patients receiving myelosuppressive chemotherapy. The drug works by stimulating the proliferation and differentiation of neutrophil precursors, helping patients maintain adequate white blood cell counts during chemotherapy.
$0.008BPart D
PeakAt peak lifecycle with modest Part D utilization (1,535 claims in 2023), suggesting a mature biosimilar competing in a crowded G-CSF market with stable but not expanding commercial opportunity.
Mechanism of Action
Pharmacologic Class:
Leukocyte Growth Factor
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (1)
An Analysis to Estimate Febrile Neutropenia (FN) in Patients Receiving Udenyca
Started Aug 2020
200 enrolled
Febrile NeutropeniaNon-myeloid Malignancy
Career Relevance
Zero linked jobs indicate limited career momentum on this product; working on UDENYCA offers experience in biosimilar commercialization, formulary strategy, and payer negotiations in a mature, highly competitive market. Career advancement is contingent on driving market share through access and pricing strategies rather than clinical innovation.
Brand Manager
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.